Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10th floor, New York, NY 10065, USA.
Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10th floor, New York, NY 10065, USA.
Surg Oncol Clin N Am. 2021 Jan;30(1):143-158. doi: 10.1016/j.soc.2020.08.005. Epub 2020 Oct 20.
Colorectal cancer (CRC) is one of the leading cancers globally in terms of both incidence and cancer-related mortality. Liver metastatic disease is the main prognostic driver for patients with CRC. The management options for liver metastatic CRC continue to evolve, particularly with the incorporation of locoregional therapies into the treatment paradigm. Hepatic arterial infusion (HAI) chemotherapy is one such liver directed approach used with the goal of converting patients to liver resection, reducing the risk of recurrence, treating recurrent disease, and most importantly improving overall survival. This article summarizes the role of HAI chemotherapy in the treatment of liver metastatic CRC.
结直肠癌（CRC）在发病率和癌症相关死亡率方面均是全球主要癌症之一。肝转移疾病是 CRC 患者的主要预后驱动因素。肝转移性 CRC 的治疗选择在不断发展，特别是将局部区域治疗纳入治疗模式。肝动脉灌注（HAI）化疗就是一种肝脏定向治疗方法，目的是使患者能够进行肝切除术，降低复发风险，治疗复发性疾病，最重要的是提高总体生存率。本文总结了 HAI 化疗在治疗肝转移性 CRC 中的作用。
